Vol. 2, Issue 1, Part A (2020)

Giant cell tumour is seen in 4% of all bone tumours and it constitutes approximately 10% of all malignant bone tumours. Preponderance is greatest between the age groups of 20 to 55 years. It is more common in females than in males ^{[1, 2]}. Tumour is known to have high post excision recurrence rate & its activity ranges from borderline to malignant lesion. It is a locally aggressive destructive lesion. Since tumour has high recurrence rates after it is treated by combination of various modalities available to reduce the recurrence rates. Tumours treated with multiple modalities have proven to have a lower recurrence rate than those tumours treated with single modalities ^{[3, 4]}. Tumour arises from the epiphyses of long bones. Most common sites are proximal tibia, distal femur, and distal radius. Radiographically, these tumours are often seen as an expansile exophytic mass. Following the multiple treatment modality in the management of Giant cell tumours, this is one case scenario.